A meta-analysis of six randomized clinical trials involving 240 children with chronic hepatitis B treated with recombinant interferon-a (IFN-a) was performed. IFN-a treatment was effective in blocking viral replication. Clearance of hepatitis B virus (HBV) DNA from sera occurred in 44 of 127 treated patients (P < .00001),and clearance of hepatitis B e antigen (HBeAg) occurred in seven of 74 treated patients (P = .099). IFN-a normalized serum levels of alanine aminotransferase (ALT) in 33 of 85 treated patients (P = .017). At the end of the follow-up period, viral replication was still reduced in IFN-a-treated patients, HBV DNA clearance occurred in 36 of 126 patients (P = .014), and HBeAg clearance occurred in 29 of 126 patients (P = .026). Regarding these virological and biochemical endpoints, we found that prolonged therapy (>6 months) was associated with a better response, whereas high dosages of IFN -a were not. These findings could be biased by limited follow-up. Children with high ALT levels had a better response. However, these randomized clinical trials had some methodological flaws, including the lack of information on histologic response to IFN-a treatment by pediatric patients and the absence of "hard outcomes" (such as survival or development of cirrhosis or hepatocellular carcinoma).
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A meta-analysis of six randomized clinical trials involving 240 children with chronic hepatitis B treated with recombinant interferon-a (IFN-a) was performed. IFN-a treatment was effective in blocking viral replication. Clearance of hepatitis B virus (HBV) DNA from sera occurred in 44 of 127 treated patients (P < .00001),and clearance of hepatitis B e antigen (HBeAg) occurred in seven of 74 treated patients (P = .099). IFN-a normalized serum levels of alanine aminotransferase (ALT) in 33 of 85 treated patients (P = .017). At the end of the follow-up period, viral replication was still reduced in IFN-a-treated patients, HBV DNA clearance occurred in 36 of 126 patients (P = .014), and HBeAg clearance occurred in 29 of 126 patients (P = .026). Regarding these virological and biochemical endpoints, we found that prolonged therapy (>6 months) was associated with a better response, whereas high dosages of IFN -a were not. These findings could be biased by limited follow-up. Children with high ALT levels had a better response. However, these randomized clinical trials had some methodological flaws, including the lack of information on histologic response to IFN-a treatment by pediatric patients and the absence of "hard outcomes" (such as survival or development of cirrhosis or hepatocellular carcinoma).
It has been reported that there are 300 million carriers of hepatitis B surface antigen (HBsAg) in the world [1] ; most of these carriers are from Asia, sub-Saharan Africa, and the Mediterranean area, where hepatitis B is mostly acquired during the perinatal period of early childhood [2, 3] . The conditions of children with sustained replication of hepatitis B virus (HBV) may progress to cirrhosis or hepatocellular carcinoma [4, 5] . It has been demonstrated that IFN-a is useful in the treatment of chronic HBV infection in adults [6] . In contrast, only a few trials of the treatment of children with chronic hepatitis B have been conducted, We performed a meta-analysis to provide a systematic overview of available information from randomized clinical trials of IFN-a treatment of children with chronic hepatitis B and to estimate the average efficacy of IFN-a treatment Methods A study search was performed with use of MEDLINE and Index Medicus (January 1986 to November 1995). Furthermore, we examined abstracts from international congresses, documentation supplied by pharmaceutical firms, and references of selected papers. Randomized clinical trials comparing IFN-a treatment with placebo or no treatment were included in the meta-analysis. Additional criteria for inclusion of trials were as follows: patients with serological markers of active HBV replication in the 6 months before entry in the trials; patients with no history of previous antiviral or immunosuppressive treatment; patients with no antibodies to hepatitis delta virus, hepatitis C virus (where available), and HIV; and patients with no history of combined treatment with IFN-a and other agents, including steroids, levamisole, and IFN-a. Finally, in randomized clinical trials where IFN-a in association with another drug was compared with IFN-a alone and a control, only the latter two treatments were considered. The outcomes evaluated were rates of clearance of HBV DNA from sera at the end of treatment and at the end of the follow-up period; rates of clearance of hepatitis B e antigen (HBeAg) at the end of treatment and at the end of the follow-up period; and normalization of serum levels of alanine aminotransferase (ALT).
To obtain an overall measure of the efficacy of IFN-a treatment, we estimated the odds ratio for every outcome and for each trial. These odds ratios were combined to provide an estimate of the overall odds ratio according to the method described by Yusuf et al. [7] . Ninety-five percent confidence intervals were calculated for the odds ratios, and the MantelHaenze1 two-tailed X 2 test was used to evaluate statistical significance [8] . We used the X 2 test for heterogeneity to assess whether the effect of variation of treatment across the randomized clinical trials was greater than expected by chance. If the results of this test are not significant, then the observed treatment effects are relatively homogeneous [7] . Sensitivity analysis was performed to assess the influence of different dosages of IFN-a, treatment length, and follow-up duration and to determine factors that could predict response to treatment with IFN-a [9] .
Results
Selection and General Characteristics of the Trials
We analyzed six randomized clinical trials of IFN-a treatment of children with chronic hepatitis B (IFN-a vs. placebo, em 1996;23 (July) two trials [10, 11] ; IFN-a vs. no treatment, four trials [12] [13] [14] [15] ). In these trials, 240 patients were enrolled to receive treatment with recombinant IFN-a. Nonrandomized studies [16] [17] [18] [19] and preliminary trials [20] were excluded from the metaanalysis.
Although the randomized clinical trials were similar and homogeneously designed and conducted, some important methodological flaws were noted (table 1): (l) Inclusion criteria were similar, but two trials involving Chinese children [10, 11] were based on evidence of viral replication and did not require a histological diagnosis, which could be an important bias for meta-analysis since some enrolled children did not have chronic hepatitis. One hundred fifty-seven patients had a histological diagnosis (chronic active hepatitis, 86; chronic persistent hepatitis, 69; and nonspecific reactive hepatitis, 2). As can be seen, histological patterns were not homogeneous because two patients' infections were classified as nonspecific reactive hepatitis [15] and some trials [14, 15] did not report a histological score (Knodell index). (2) Randomization criteria and criteria for power analysis (determination of the number of patients needed to obtain a significant result, with low a and f3 errors)
were not reported, and the sample sizes were probably too small to show statistically significant differences. These problems are important in evaluating randomized clinical trials. (3) The probable time of infection (i.e., perinatal vs. later in infancy) and its influence on the success of the therapy were not analyzed adequately.
(4) Histological outcome was evaluated in only two trials [12, 13] . We believe that histological outcome is a crucial endpoint, and lack of a control biopsy is an important bias in randomized clinical trials. Moreover, Knodell indexes before and after therapy were not reported for each patient. Thus, liver histology was not evaluated in this meta-analysis. (5) Follow-up periods after treatment varied (range, 6-18 months). Follow-up was complete for 239 patients. Because response to IFN-a is often delayed for 3-6 months after stopping this therapy, follow-up should have been longer; two trials [13, 14] had limited follow-ups after treatment. Furthermore, no trial considered "hard outcomes," including progression to cirrhosis, heptocellular carcinoma, and survival (which are clinically important endpoints). (6) Additional biases included the lack of placebo for the control group, except in two trials [10, 11] , and the lack of blinded evaluation of data. Other clinical characteristics, treatment regimens, and findings that were reported in the six randomized clinical trials are listed in table 2. As can be seen, the ages of the enrolled children ranged from 1.5 to 17 years. All patients had markers of HBV replication (HBsAg, HBeAg, and HBV DNA) for at least 6 months before enrollment in the trials. IFN-a dosages ranged from 3 to 10 MU (million unitsj/nr' three times a week intramuscularly or subcutaneously. However, various dosages of IFN-a that were used in the trials were not related to the severity of hepatitis B according to viral burden or the degree of elevation of the ALT level. Treatment lengths ranged from 3 to 12 months. Rates of clearance of HBV DNA from sera at the end of treatment and at the end of the follow-up period were reported in all six trials (240 patients). Rates of clearance of HBeAg from sera at the end of therapy and at the end of the follow-up period were reported in four trials (135 patients) and six trials (240 patients), respectively. Rates of normalization of ALT levels following treatment were reported in four trials (147 patients). Decreased histological evidence of inflammatory activity was considered an outcome in two trials (60 patients) [12, 13] .
Results of the Meta-Analysis
Six randomized clinical trials involving a total of240 pediatric patients with chronic hepatitis B were included in the metaanalysis. The proportions of clearance ofHBV DNA from sera at the end of IFN-a treatment and at the end of follow-up are shown in tables 3 and 4, respectively. As can be seen, serum levels ofHBV DNA were markedly and significantly decreased at the end of treatment with IFN-a (P < .00001). The results of a sensitivity analysis of factors associated with a better prolonged response to IFN-a treatment are shown in table 8. Although prolonged therapy (6-12 months) was associated with a better virological response, higher doses of IFN-a were not associated with more benefit. Moreover, longterm response was better in those patients with higher ALT levels before treatment. In particular, a long-term response to IFN-a treatment was noted in 13 (44.8%) of 29 patients with ALT levels more than twice the upper limit of normal and in two (6.3%) of 32 patients with ALT levels less than or twice the upper limit of normal (OR, 8.9; 95% CI, 2.5-30.7; P = .0005). In untreated patients, long-term response was observed in six (25%) of 24 patients with ALT levels more than twice the upper limit of normal and in two (5.7%) of 35 patients with ALT levels less than or twice the upper limit of normal (OR, 7.8; 95% CI, 1.5-40.3; P = .012). Clearance of HBsAg from sera was noted in two (1.6%) of 127 treated patients and in none of 113 untreated children (OR, 7.2; 95% CI, 0.4-99.9; P = .16). Adverse effects due to IFN-a treatment that required reduction or discontinuation of therapy occurred in six (4.7%) of 127 treated patients (OR, 7.5; 95% CI, 1.4-38.5; P = .014). These side effects were neutropenia (3 patients), persistent fever with arthromyalgias (2), and thrombocytopenia (1).
We also assessed the "number to treat" [21] , a measure of the number of patients needing treatment, to determine the results for one patient. We had to treat 7.1 children to measure one patient's long-term clearance ofHBV DNA from sera that was due to IFN-a. We had to treat 8.0 patients to observe clearance of HBeAg from sera in one patient and 5.6 patients to see normalization of ALT levels in one patient. If we considered only children with ALT levels more than twice the upper limit of normal, we had to treat only 2.5 patients to observe the virological response to IFN-a in one patient.
Discussion
Despite progress in understanding the biology of HBV, specific treatments for chronic hepatitis B in children are limited. Several studies evaluating the efficacy of several treatments, including IFN-a alone, IFN-a and steroids [11, 22] , IFN-a and levamisole [23] , and IFN-y and IFN-a [24] , have been performed. However, there is not a definitive therapy for chronic hepatitis B, a serious disease that may progress to cirrhosis and hepatocellular carcinoma in childhood.
We noted several methodological flaws in the randomized clinical trials analyzed in this study. In particular, sensitivity analysis stressed the relevance of histologic evaluation because trials based on clinical diagnoses had significantly different outcomes in comparison with those based on biopsy-proven diagnoses. The results of this meta-analysis strengthen the limited and partial findings of the six randomized clinical trials: IFN-a is efficacious on the basis of virological and biochemical endpoints assessed in these trials. Although a favorable cost/benefit ratio of IFN-a treatment of adult patients with chronic hepatitis B has been reported [25] , this ratio still needs to be defined for children with chronic hepatitis B. Furthermore, response rates seem to be lower among children than among adult patients. A long-term virological benefit (clearance of HBV DNA and HBeAg) was described in 30%-40% of adult patients with chronic hepatitis C [26] , whereas 23%-28% of our pediatric patients had a long-term virological response. Tine et al. [27] questioned the clinical efficacy ofIFN-a treatment of adult patients with chronic hepatitis B, since previous randomized clinical trials evaluated only short-term responses based on biochemical and virological endpoints. These investigators suggested that the efficacy of IFNa treatment also has to be confirmed by clinical endpoints, including cirrhosis, liver failure, and death. We also noted that the follow-up periods in the six randomized clinical trials were generally short, even though an exacerbation of the disease may occur several months after the end of therapy.
Brook and co-workers [28] demonstrated that clearance of HBeAg and HBV DNA from sera from adults treated with IFNa was efficaciously associated with clearance of hepatitis B core antigen and HBeAg from the liver. In children treated with IFN-a, clearance of HBV DNA from sera was associated with clearance ofHBV DNA from the liver [29] . Since the statistical significance of the efficacy ofIFN-a treatment decreases when the follow-up period is sufficiently prolonged, it has been suggested that IFN-a simply hastens the immunologic clearance of the virus in children, ofwhom 5%-30% per year spontaneously clear HBeAg [13, 30] . IFN-a treatment could consequently reduce the infectivity of children with respect to their community and decrease the amount of integrated HBV DNA in liver cells [15] .
The "number to treat" approach suggests that there are subgroups of patients for whom IFN-a treatment is more advantageous. The "rationale" for IFN-a treatment is to identify patients who may respond to treatment and the best schedule for treatment. It seems that long-term treatment (6-12 months) at a dosage of~5 MU/m 2 thrice a week may be more effective and better tolerated. Furthermore, higher serum levels of aminotransferases (more than twice the upper limit of normal) are associated with a significantly better response to IFN-a treatment. On the other hand, low viral replication, which is detected by low serum levels of HBV DNA, has been reported to be associated with a better response to IFN-a treatment [22] . Thus, patients with an active immunologic response to HBV have more pronounced hepatic cytolysis and lower viral replication. The antiviral and immunoregulatory properties of IFNa treatment are more likely to be advantageous for these patients. Response to IFN-a treatment may be better in children with horizontally acquired HBV infection [31] , whereas vertically acquired HBV infection is characterized by the development of immunologic tolerance, high viral replication, and nor-mal ALT levels; the risk of chronic hepatitis developing in patients with these infections is 90% [32] . Finally, we confirmed that clearance of HBsAg from sera is a rare event.
In conclusion, although IFN-a therapy seems to be efficacious for chronic hepatitis B in children, the limited duration of follow-up, the limited clinical importance of the molecular and biochemical endpoints considered, the lack of histological evaluation, and the remarkable cost and side effects of IFN-a that were noted in the meta-analysis of six randomized clinical trials should warn physicians about the wide use of IFN-a treatment of children. Further studies are needed to assess the real cost/benefit ratio of IFN-a treatment of pediatric patients, the best schedule for IFN-a treatment, and the optimal duration oflFN-a treatment, and a better evaluation of clinical, virological, and histological markers of response to IFN-a treatment is also needed. Long-term follow-up and histological evaluation should be mandatory in these studies.
